Premium
TREATMENT OF POST MENOPAUSAL OSTEOPOROSIS. A CONTROLLED THERAPEUTIC TRIAL COMPARING OESTROGEN/GESTAGEN, 1,25‐DIHYDROXY‐VITAMIN D 3 AND CALCIUM
Author(s) -
JENSEN G. FINN,
CHRISTIANSEN C.,
TRANSBØL I.
Publication year - 1982
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1982.tb02769.x
Subject(s) - medicine , osteoporosis , endocrinology , vitamin d and neurology , calcium , hypercalcaemia , bone mineral , cortical bone , metabolite , estrogen , pathology
A controlled therapeutic trial on seventy‐four 70‐year‐old women was carried out with the purpose of finding the optimal treatment for post menopausal osteoporosis. The bone mineral content (BMC) was measured by 125 I‐photonabsorptiometry at two sites in the distal part of the forearms, where the trabecular/cortical ratio is 0·25 and 1·5, respectively. Radiographs were done on the right hand to measure the metacarpal bone mass (cortical area/total area = CA/TA). After observing the spontaneous course of bone loss for 6 months the participants were allocated at random to 12 months’treatment with 1,25‐dihydroxycholecalciferol [1,25(OH)2D 3 ] and oestrogen/gestagen, alone or in combination, and calcium. The groups treated with oestrogen/gestagen [with or without 1,25(OH) 2 D 3 ] showed a highly significant increase in BMC. In contrast bone mineral remained unchanged or decreased in both the calcium and the 1,25(OH) 2 D 3 groups with a tendency towards more pronounced negative bone balance in the 1,25‐(OH) 2 D 3 group. Seven out of nineteen patients on 1,25(OH) 2 D 3 developed hypercalcaemia, which necessitated a reduction in dosage. It is concluded that the new vitamin D metabolite, 1,25(OH) 2 D 3 , given in clinically acceptable doses, is without value in the treatment of post menopausal osteoporosis.